

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

Board on Health Sciences Policy
Roundtable on Translating Genomic-Based Research for Health
Forum on Drug Discovery, Development, and Translation

Deriving Drug Discovery Value from Large-Scale Genetic Bioresources:
A Workshop
March 22, 2016

The Keck Center of the National Academies, Room 100
500 Fifth Street, NW
Washington, DC 20001

MEETING OBJECTIVES

- TO ADDRESS HOW PROGRESS CAN BE MADE IN DISCOVERING AND VALIDATING PROMISING TARGETS AND MEDICINES FOR THOSE TARGETS BY USING DATA COLLECTED FROM LARGE-SCALE GENETIC STUDIES
- TO HIGHLIGHT CURRENT GENOMIC-ENABLED DRUG DISCOVERY ACTIVITIES IN INDUSTRY, ACADEMIA, AND GOVERNMENT AND SHARE BEST PRACTICES FOR STUDY DESIGN AND DATA COLLECTION
- TO EXAMINE ENABLING PARTNERSHIPS AND BUSINESS MODELS TO FACILITATE THE USE OF GENETIC DATA FOR DRUG DISCOVERY

AGENDA

7:45–8:30 A.M.	Breakfast Available
8:30–8:35 A.M.	Welcoming Remarks
	Geoffrey Ginsburg, <i>Genomics Roundtable Co-Chair</i> Director, Duke Center for Applied Genomics & Precision Medicine; Professor of Medicine and of Pathology and Biomedical Engineering, Duke University Medical Center
	Russ B. Altman, <i>Drug Forum Co-Chair</i> Professor of Bioengineering, Genetics, and Medicine Stanford University
8:35–8:45 A.M.	Charge to workshop speakers and participants
	Nadeem Sarwar, <i>Workshop Chair</i> President, Andover Product Creation Innovation Systems Eisai Inc.

SESSION I: DESIGNING COHORTS TO MAXIMIZE DISCOVERY CAPABILITIES

Objectives: To explore current gaps and opportunities in data collected in large cohort studies and what elements could enable a robust discovery toolbox.

Moderator: Geoff Ginsburg, *Genomics Roundtable Co-Chair; Director, Duke Center for Applied Genomics & Precision Medicine*

8:45–9:30 A.M. Joe Vockley
Chief Operating Officer and Chief Scientific Officer
Senior Vice President
Inova Translational Medicine Institute

Mark Daly
Co-director
Program in Medical and Population Genetics
Broad Institute

Aris Baras
Vice President, Co-Head Regeneron Genetics Center
Regeneron Pharmaceuticals

9:30–9:45 A.M. **Break**

Kári Stefánsson
Chairman, CEO, and Founder
deCODE Genetics

Richard Scheller
Chief Science Officer
23andMe

10:15–10:45 A.M. **Discussion with Speakers and Attendees**

SESSION II: CURRENT GENOME-ENABLED DISCOVERY ACTIVITIES RELATED TO BIORESOURCES

Objectives: To discuss current activities among stakeholder groups and innovative technologies, to identify gaps, and to explore opportunities for cross-sector engagement.

Moderator: John Carulli, Director, Precision Medicine, Biogen

10:45–12:00 P.M. Russ Altman
Professor of Bioengineering, Genetics, and Medicine
Stanford University

Lon Cardon
Senior Vice President of Alternative Discovery and Development
Head of Target Sciences
GlaxoSmithKline

Sohini Chowdhury
Senior Vice President, Research Partnerships
Michael J. Fox Foundation

Sally John
Vice President
Computational Biology and Genomics
Biogen Idec

Tim Rolph
Vice-President Program Value Enhancement
Pfizer

12:00–12:45 P.M. **Discussion with Speakers and Attendees**

12:45–1:45 P.M. **WORKING LUNCH**

SESSION III: BUSINESS MODELS THAT SUPPORT BIORESOURCE DISCOVERY COLLABORATION

Objectives: To examine potential precompetitive business models and investments that can support discovery efforts and opportunities across stakeholder groups.

Moderator: Rajesh Ranganathan, Vice President of Science and Regulatory Advocacy, PhRMA

1:45–2:45 P.M. Lynn Matrisian
Vice President, Scientific & Medical Affairs
Pancreatic Cancer Action Network

Meg Ehm
Director, External Strategic Alliances
Genetics
GlaxoSmithKline

David Wholley, Accelerating Medicines Partnership and fNIH
Director, Research Partnerships
Foundation for the National Institutes of Health

Chas Bountra
Professor of Translational Medicine
Head of Structural Genomics Consortium

University of Oxford

2:45–3:30 P.M. **Discussion with Speakers and Attendees**

3:30–3:45 P.M. **BREAK**

SESSION IV: WHERE DO WE GO FROM HERE?

Objectives: What are the short-term and long-term next steps for achieving effective collaboration among stakeholders? Are there incentives that should be explored? How can we maximize use of large-scale genetic bioresources to effectively translate research to drug discovery?

Moderator: Nadeem Sarwar, *Workshop Chair; President, Andover Product Creation Innovation Systems, Eisai Inc.*

3:45–3:55 P.M. **Dan Tagle (10 min. presentation)**
Associate Director for Special Initiatives
Office of the Director
National Center for Advancing Translational Sciences
National Institutes of Health

3:55–4:25 P.M. **Panel Discussion (5 min. remarks each)**
Chas Bountra
Mark Daly
Richard Scheller
Russ Altman
Lynn Matrisian
Lon Cardon

4:25–5:10 P.M. **Discussion with Speakers and Attendees**

5:10–5:25 P.M. **SESSION HIGHLIGHTS (5 min. remarks each)**
Geoff Ginsburg
John Carulli
Rajesh Ranganathan

5:25–5:30 P.M. **CONCLUDING REMARKS**

Nadeem Sarwar, *Workshop Chair*
President, Andover Product Creation Innovation Systems
Eisai Inc.

5:30 P.M. **ADJOURN**